Navigenics Founder Blasts Myriad's BRACAnalysis Pricing | GenomeWeb

On the heels of Angelina Jolie's revelation that she underwent a preventive double mastectomy, a Navigenics founder is taking aim at Myriad Genetics' price for its BRACAnalysis test.

In an op-ed piece appearing in the New York Times, David Agus also calls for legislative changes to bar healthcare companies from having monopolies on technologies that have life and death implications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Biotech Court

At a Cost

Higher Postdoc Pay

From Poets to Galileo

Increased Coverage

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."